New drug targets Hard-to-Treat cancers in early trial
NCT ID NCT04617314
First seen Jan 11, 2026 · Last updated May 11, 2026 · Updated 23 times
Summary
This early-phase study tested an experimental drug called RC108-ADC in 67 adults with advanced solid tumors that have a specific protein (c-Met). The main goals were to check safety, find the best dose, and see if the drug shrinks tumors. Participants received the drug by injection, and researchers monitored side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, China
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
-
The First Hospital of Jilin University
Changchun, Jilin, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.